Digital Therapeutics Today - October 7, 2026

Daily digital therapeutics roundup: 6 stories curated October 7, 2026. Lead: Click claims FDA okay for first-in-class schizophrenia DTx.

The latest in digital therapeutics: 6 developments from the past day, tracked and curated by the HealthTech Cube news desk. The lead story: Click claims FDA okay for first-in-class schizophrenia DTx.

Click claims FDA okay for first-in-class schizophrenia DTx

pharmaphorum2026-10-06

Digital Therapeutics Market Set to Reach US$39.52 Billion

openPR.com2026-10-06

FDA clears Click Therapeutics' Motivista, first treatment for negative schizophrenia symptoms

Dealroom2026-10-06

FDA Clears Prescription Digital Therapeutic for Negative Symptoms of Schizophrenia

Neurology Advisor2026-10-06

FDA Clearance Positions Click Therapeutics’ Motivista for Commercial Rollout

TipRanks2026-10-06

FDA Clears Motivista (CT-155), the First Authorized Treatment for Negative Schizophrenia Symptoms

The Manila Times2026-10-05

Follow the full firehose on the HTC Wire, refreshed automatically every day.

Reach the people behind these stories. HealthTech Cube demand gen programs deliver qualified healthcare technology leads from $49.50 per lead - see packages or download the 2026 media kit.